Baldomero, Arianne K.

Abstract Rationale Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United States. Rural populations experience a disproportionate burden, which likely reflects a combination of factors, including limited access to evidence-based COPD care. Our aim was to identify barriers, facilitators, and recommendations to improve the quality of COPD care received by rural veterans. Methods We performed a qualitative study of veterans with COPD who lived in rural areas. Participants were drawn from the Minneapolis VA Health Care System and the St. Cloud VA Health Care System. We conducted semi-structured interviews to explore rural veterans’ personal experiences navigating the healthcare system to receive COPD care. Interviews were conducted via telephone and were transcribed using NVIVO software. Transcribed interviews were then coded using content analysis. Results - Participants (N = 27) ranged in age from 59 to 85 years of age, 4 (14.8%) were women, and 24 (88.9%) identified as white. - Most veterans, 12 (44.4%) had an 11 to 30 minute drive to their primary care provider and 13 (48.1%) had a greater than 1 hour drive time to the pulmonologist. - Twenty-four (88.9%) participants had at least one exacerbation in the past 12 months, 10 (41.7%) of which ended up hospitalized. - Elucidative quotes are listed in Table 1, which were used to identify general themes. - General Themes: Barriers Primary care provider turnover and shortages, physical limitations related to chronic medical conditions, discomfort with virtual care, long appointment wait times and limited scheduling flexibility, complex referral processes, transportation challenges, and weather-related difficulties. Facilitators Self-motivation, self-advocacy, support from family and friends, timely scheduling and communication, trust and continuity with healthcare providers, and familiarity with or outside assistance in using technology facilitated access to COPD care. Recommendations Participants suggested improving technology-related education, providing necessary technology equipment, enhancing access to clinic appointments, supporting provider continuity, and fostering timely communication between patients and healthcare teams. Conclusion This study identified several barriers, facilitators, and patient-generated recommendations to improve COPD-related care for rural veterans. Participants described physical limitations, lack of provider continuity, and challenges with technology navigation as key barriers. Facilitating factors included strong family support and a sense of self-sufficiency that motivated engagement in care. Recommendations for improvement emphasized enhanced communication, greater patient education, and additional support for using technology in healthcare delivery. This abstract is funded by: NIH

Abstract RATIONALE The best described endotype of COPD is alpha-1 antitrypsin (AAT) deficiency, which is due to a genetic abnormality in the SERPINA1 gene. Homozygotes for the Z allele (PI[asterisk]ZZ individuals) carry the genotype most commonly associated with severe AAT deficiency, but a highly prevalent endotype is the heterozygous state (PI[asterisk]MZ individuals). Here we test the hypothesis that individuals with PI[asterisk]MZ genotype are at higher risk for COPD exacerbation and healthcare utilization compared to those with no pathogenic variants in the SERPINA1 gene (PI[asterisk]MM individuals). METHODS Real-world data on 4,456 individuals with available AAT genotyping were extracted from the Cleveland Clinic Health System (CCHS) electronic health records (EHR) and analyzed to compare the risk of moderate COPD exacerbation (defined as a short-term steroid prescription), all-cause emergent care (defined as an express care visit, urgent care visit, or emergency department visit), and all-cause hospitalization between individuals with PI[asterisk]MZ vs. PI[asterisk]MM genotypes. Cox proportional hazards models were used to adjust for age, sex, race, BMI, smoking status, comorbidity count, liver disease diagnosis, and median income by zip code.To assess the effect of AAT levels on outcomes, we categorized participants into three groups based on AAT level and used 90 mg/dL as a threshold given it is the lower limit of the normal reference range and genotype: MM individuals with an AAT level >90 mg/dL, MZ >90 mg/dL and MZ <90 mg/dL. To assess the effect of PI[asterisk]MZ genotype among individuals with pre-existing lung disease, we performed a subgroup analysis of individuals with at least a six-month inhaler prescription. RESULTS In this cohort, 308 individuals had a PI[asterisk]MZ genotype. PI[asterisk]MZ was associated with increased risk for moderate COPD exacerbations (adjusted HR [95% CI]: 1.66 [1.27, 2.17]) and hospitalizations (adjusted HR [95% CI]: 1.44 [1.19, 1.75]) compared to PI[asterisk]MM. The risk of hospitalization was higher among PI[asterisk]MZ individuals with AAT levels <90 mg/dL (adjusted HR [95% CI]: 1.59 [1.14, 2.23]) but not in those with AAT levels >90 mg/dL, as compared to PI[asterisk]MM. Sensitivity analysis in those treated with inhaler therapy showed overall similar results. CONCLUSIONS Increased hospitalizations and moderate COPD exacerbations among PI[asterisk]MZ individuals compared to PI[asterisk]MM individuals merit future prospective studies to better characterize the longitudinal course and healthcare utilization among those with an PI[asterisk]MZ genotype. Given the high prevalence of these carriers globally, PI[asterisk]MZ represents a COPD phenotype that invites additional investigation to identify biomarkers of worse disease and treatable traits.